SGT-1001 is the first development candidate using SalioGen’s…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
IN THE NEWS
Ophthalmology industry veteran brings 20 years of experience…
OPGx-LCA5 will advance to the next highest dose in mid-2024 …
FORT WORTH, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Nacuity…
• No serious adverse events in the first two cohorts of pat…
Divestment of sepofarsen and ultevursen completed – Théa to …
ATSN-101 continues to demonstrate clinically meaningful impr…
RMAT designation recognizes the potential of ATSN-101 to add…
Data to be presented as part of gene augmentation therapy pr…
NVasc is developing a therapeutic angiogenesis strategy for …
Milestone broadens partnership to develop novel ocular thera…
OPGx-LCA5 is designed to address vision loss due to Leber co…